文献速递外周动脉疾病

BEST-CLI试验中血运重建时WIfI分期与生活质量的关系

Relationship between WIfI stage and quality of life at revascularization in the BEST-CLI trial.
PubMed 文献 · J Vasc Surg · 2022-11-23

基于BEST-CLI前瞻性随机试验数据,分析1568例慢性肢体威胁性缺血(CLTI)患者的WIfI分期与基线健康相关生活质量(HRQoL)的关系。多变量分析显示,WIfI 4期较1-3期与更低的SF-12心理成分评分和SF-6D R2效用指数评分独立相关,而与血管生活质量、SF-12躯体成分及EQ-5D无独立关联。结论认为WIfI分期与CLTI患者因心理健康而非躯体健康导致的生活质量较差独立相关。

要点

  • WIfI 4期较1-3期与更低的SF-12心理成分评分独立相关(估计值-2.43,95%CI -3.73至-1.13,P<.001)。
  • WIfI 4期较1-3期与更低的SF-6D R2效用指数评分独立相关(估计值-0.02,95%CI -0.03至0.001,P=.04)。
  • WIfI分期与基线血管生活质量、SF-12躯体成分及EQ-5D无独立关联。

核心结论

  • WIfI分期与CLTI患者因心理健康而非躯体健康导致的生活质量较差独立相关。
  • 临床医生应了解肢体损害最严重患者所承受的心理压力负担。

研究设计与样本

  • BEST-CLI试验为前瞻性随机试验,比较开放与血管内血运重建策略。
  • 查询患者入组时的HRQoL评估数据,共分析1568例具有完整WIfI数据的患者,其中71.5%为男性。
  • WIfI分布为4期35.5%、3期29.6%、2期28.6%、1期6.3%。
  • 采用多变量回归分析识别与基线HRQoL评估的独立关联。

主要发现

  • WIfI 4期较1-3期患者更多为男性(74.9% vs 69.6%)、当前吸烟者(25.4% vs 17.6%)、有终末期肾病(13.3% vs 8.5%)和糖尿病(83.6% vs 60.2%)、不能独立行走(56.8% vs 38.5%),中位合并症评分更高(4 vs 3;所有P<.05)。
  • 多变量分析中,WIfI 4期较1-3期与更低的SF-12心理成分量表评分相关(估计值-2.43;95%CI -3.73至-1.13;P<.001)。
  • WIfI 4期较1-3期与更低的SF-6D R2效用指数评分相关(估计值-0.02;95%CI -0.03至0.001;P=.04)。
  • WIfI分期与基线血管生活质量、SF-12躯体成分量表及EQ-5D评估无独立关联。

关键数值与推荐

  • WIfI 4期较1-3期与更低的SF-12心理成分评分独立相关(估计值-2.43;95%CI -3.73至-1.13;P<.001)。
  • WIfI 4期较1-3期与更低的SF-6D R2效用指数评分独立相关(估计值-0.02;95%CI -0.03至0.001;P=.04)。
  • WIfI分期与基线血管生活质量、SF-12躯体成分及EQ-5D无独立关联。

临床怎么用

  • 临床医生应了解肢体损害最严重患者所承受的心理压力负担。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The WIfI (Wound, Ischemia, foot Infection) stage measures the extent of wounds, ischemia, and foot infection in patients with chronic limb threatening ischemia (CLTI) and has been associated with the risk of major amputation. Patients with CLTI have impaired health-related quality of life (HRQoL), which can be multifactorial. We hypothesized that the severity of the limb threat (WIfI stage) would be associated with poor HRQoL among patients with CLTI presenting for revascularization. METHODS: The dataset of the BEST-CLI (best endovascular versus best surgical therapy in patients with CLTI) trial, a prospective, randomized trial comparing open and endovascular revascularization strategies, was queried for HRQoL assessments at patient enrollment. The HRQoL assessments included (1) Vascular Quality of Life; (2) 12-item short form survey (SF-12), containing the utility index score (short-form six-dimension R2 utility index, incorporating physical, emotional, and mental well-being) and mental and physical components; and (3) the EQ-5D. Multivariable regression analysis was used to identify the independent associations with the baseline HRQoL assessments. RESULTS: A total of 1568 patients with complete WIfI data were analyzed, of whom 71.5% were men. The WIfI distribution was 35.5% with stage 4, 29.6% with stage 3, 28.6% with stage 2, and 6.3% with stage 1. Patients presenting with WIfI stage 4, compared with stage 1 to 3, were more often men (74.9% vs 69.6%) and current smokers (25.4% vs. 17.6%), had had end-stage renal disease (13.3% vs 8.5%) and diabetes (83.6% vs 60.2%), were not independently ambulatory (56.8% vs 38.5%), and had had higher median morbidity scores (4 vs 3; P < .05 for all). On multivariable analysis, WIfI stage 4, compared with stage 1 to 3, was associated with lower SF-12 mental component scale scores (estimate, -2.43; 95% confidence interval, -3.73 to -1.13; P < .001) and short-form six-dimension R2 utility index scores (estimate, -0.02; 95% confidence interval, -0.03 to 0.001; P = .04). The WIfI stage was not independently associated with the baseline Vascular Quality of Life, SF-12 physical component scale, or EQ-5D assessments. CONCLUSIONS: WIfI stage was independently associated with poorer quality of life because of mental, rather than physical, health for patients with CLTI. Clinicians should be aware of the burden of mental stress borne by those with the greatest limb impairment.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Siracuse JJ, Rowe VL, Menard MT, et al. Relationship between WIfI stage and quality of life at revascularization in the BEST-CLI trial. J Vasc Surg. 2022. PMID: 36435274. doi:10.1016/j.jvs.2022.11.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。